Anti-PCSK9 Drugs: An Ingenious Solution for a Problem That's Mostly Already Solved – Forbes

Anti-PCSK9 Drugs: An Ingenious Solution for a Problem That’s Mostly Already Solved
Forbes
On Friday, for the first time, we saw the full data from the FOURIER clinical trial of Amgen’s cholesterol-lowering antibody, evolocumab (Repatha™). Depending on who you listen to, it was either “the most important study in at least 20 years” or a …
Cholesterol drug cuts heart risks, spurs new cost debateRutland Herald
An End to Heart Disease? Not QuiteNew York Times
No evidence of cognitive issues when evolocumab added to statin therapyMedical Xpress
FierceBiotech –Science Times –Zacks.com –Bloomberg
all 276 news articles »